Business Context and Reporting Period
This Form 8-K filing by LeMaitre Vascular, Inc. (the "Company") reports on events occurring on December 12, 2007, with the report dated December 17, 2007. The filing addresses corporate governance changes, specifically the appointment of a new director to restore compliance with Nasdaq Marketplace Rules following the resignation of an independent director in August 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on director compensation arrangements and governance compliance.
- Director Compensation (Russell D. Hays): Annual retainer of $17,500 (comprising $10,000 for Board membership, $5,000 for Chair of Nominating and Corporate Governance Committee, and $2,500 for Audit Committee membership).
- Stock Option Grant: Non-statutory option to purchase 20,000 shares of common stock, granted at market value on the date of grant.
- Meeting Fees: Additional fees apply for attendance at Board and committee meetings (e.g., $2,500 per in-person Board meeting).
- Compensation Cap: No eligible director may receive more than $40,000 in any calendar year without specific Board approval.
Material Changes
The primary material change is the appointment of Russell D. Hays as a director, effective January 1, 2008. He was appointed to the Audit Committee (as Chair) and the Nominating and Corporate Governance Committee (as Chair). This appointment is intended to cure the Company's noncompliance with Nasdaq rules regarding the independence of the Board and the composition of the Audit Committee, which resulted from the resignation of Guido J. Neels in August 2007.
Guidance, Outlook, and Risks
Outlook: The Company expects to regain compliance with Nasdaq Marketplace Rules 4350(c)(1) and 4350(d)(2) upon review by Nasdaq in January 2008. The appointment falls within the permitted cure period (one year from the vacancy event).
Risks and Contingencies: The filing highlights the risk of noncompliance with Nasdaq listing standards due to a lack of independent directors and an insufficiently staffed Audit Committee. The appointment of Mr. Hays is the specific remedial action taken to mitigate this risk.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the effective date of Russell D. Hays' appointment (January 1, 2008) and his specific committee roles.
- Confirm the details of the 20,000-share stock option grant, including vesting schedule (three equal annual installments) and expiration (five years).
- Monitor the Company's status regarding Nasdaq compliance in January 2008 following the appointment.
- Review the Company's Non-Employee Director Compensation Policy for potential changes to the $40,000 annual cap or fee structures.